SRDX Stock Recent News
SRDX LATEST HEADLINES
SurModics (SRDX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.36 per share. This compares to loss of $0.40 per share a year ago.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #EarningsCall--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 1. Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, May 1, to discuss the second quarter fiscal 2024 financial results and accomplishments and.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.50 per share a year ago.
Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.